midazolam has been researched along with Complex Regional Pain Syndromes in 5 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Complex Regional Pain Syndromes: Conditions characterized by pain involving an extremity or other body region, HYPERESTHESIA, and localized autonomic dysfunction following injury to soft tissue or nerve. The pain is usually associated with ERYTHEMA; SKIN TEMPERATURE changes, abnormal sudomotor activity (i.e., changes in sweating due to altered sympathetic innervation) or edema. The degree of pain and other manifestations is out of proportion to that expected from the inciting event. Two subtypes of this condition have been described: type I; (REFLEX SYMPATHETIC DYSTROPHY) and type II; (CAUSALGIA). (From Pain 1995 Oct;63(1):127-33)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To describe the treatment of an intractable complex regional pain syndrome I (CRPS-I) patient with anesthetic doses of ketamine supplemented with midazolam." | 7.74 | Complete recovery from intractable complex regional pain syndrome, CRPS-type I, following anesthetic ketamine and midazolam. ( Altemeyer, KH; Kiefer, RT; Ploppa, A; Rohr, P; Schwartzman, RJ, 2007) |
| "To describe the treatment of an intractable complex regional pain syndrome I (CRPS-I) patient with anesthetic doses of ketamine supplemented with midazolam." | 3.74 | Complete recovery from intractable complex regional pain syndrome, CRPS-type I, following anesthetic ketamine and midazolam. ( Altemeyer, KH; Kiefer, RT; Ploppa, A; Rohr, P; Schwartzman, RJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, SP | 2 |
| Hameed, H | 2 |
| Kurihara, C | 1 |
| Pasquina, PF | 2 |
| Patel, AM | 1 |
| Babade, M | 1 |
| Griffith, SR | 1 |
| Erdek, ME | 1 |
| Jamison, DE | 1 |
| Hurley, RW | 2 |
| Wasan, AD | 1 |
| Manchikanti, L | 1 |
| Benyamin, RM | 1 |
| Candido, KD | 1 |
| Hirsch, JA | 1 |
| Kiefer, RT | 1 |
| Rohr, P | 1 |
| Ploppa, A | 1 |
| Altemeyer, KH | 1 |
| Schwartzman, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Cross-over Study Evaluating the Effect of Sedation on Pain Relief After Diagnostic Injections[NCT01472835] | 73 participants (Actual) | Interventional | 2011-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measure of functional capacity on a scale ranging from 0% to 100%, with 0% signifying no disability (NCT01472835)
Timeframe: 1-month
| Intervention | units on a scale (Mean) |
|---|---|
| Sedation | 34.8 |
| Control | 40.6 |
0-10 numerical rating scale (NRS) pain scale. 0 being no pain and 10 being the worst possible pain. (NCT01472835)
Timeframe: 1-month
| Intervention | units on a scale (Mean) |
|---|---|
| Sedation | 5.1 |
| Control | 5.6 |
pain diary using 0-10 scale, with 0 being no pain and 10 being the worst pain imaginable (NCT01472835)
Timeframe: through 6 hours after injection
| Intervention | units on a scale (Mean) |
|---|---|
| Sedation | 2.2 |
| Control | 3.4 |
0-10 pain scale, with 0 being no pain and 10 being the worst pain imaginable (NCT01472835)
Timeframe: 1 day
| Intervention | units on a scale (Mean) |
|---|---|
| Sedation | 3.1 |
| Control | 5.5 |
5-point Likert scale. The scale is from 1-5. 1 being very unsatisfied and 5 being very satisfied. (NCT01472835)
Timeframe: 1 day
| Intervention | units on a scale (Mean) |
|---|---|
| Sedation | 4.0 |
| Control | 3.6 |
1 trial available for midazolam and Complex Regional Pain Syndromes
| Article | Year |
|---|---|
The effect of sedation on the accuracy and treatment outcomes for diagnostic injections: a randomized, controlled, crossover study.
Topics: Adult; Aged; Anesthetics, Intravenous; Autonomic Nerve Block; Complex Regional Pain Syndromes; Consc | 2014 |
4 other studies available for midazolam and Complex Regional Pain Syndromes
| Article | Year |
|---|---|
Efficacy vs effectiveness and explanatory vs pragmatic: where is the balance point in pain medicine research?
Topics: Anesthetics, Intravenous; Autonomic Nerve Block; Complex Regional Pain Syndromes; Conscious Sedation | 2014 |
Sedation for diagnostic injections: prioritizing patient interests.
Topics: Anesthetics, Intravenous; Autonomic Nerve Block; Complex Regional Pain Syndromes; Conscious Sedation | 2014 |
Cohen et al. Reach inappropriate conclusions on the effect of sedation on the accuracy and treatment outcomes for diagnostic injections.
Topics: Anesthetics, Intravenous; Autonomic Nerve Block; Complex Regional Pain Syndromes; Conscious Sedation | 2014 |
Complete recovery from intractable complex regional pain syndrome, CRPS-type I, following anesthetic ketamine and midazolam.
Topics: Adolescent; Analgesics; Complex Regional Pain Syndromes; Disease Progression; Female; Follow-Up Stud | 2007 |